BeiGene
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Executives
8BeiGene Management Team
8 Team Members
BeiGene has 8 executives. BeiGene's founder is Pearl Huang. BeiGene's current Founder, Chief Executive Officer is John V Oyler.
Name | Work History | Title | Status |
|---|---|---|---|
Pearl Huang | Cygnal Therapeutics, Roche Venture Fund, GSK, Merck & Co., DuPont, and Merck Research Ventures Fund | Founder | Current |
John V Oyler | BioDuro, Galenea, Telephia, Genta, and McKinsey & Company | Founder, Chief Executive Officer | Current |
Lusong Luo | Senior Vice President | Current | |
Jason Yang | Senior Vice President | Current | |
Wendy Yan | Managing General Partner | Current |
Name | Pearl Huang | John V Oyler | Lusong Luo | Jason Yang | Wendy Yan |
|---|---|---|---|---|---|
Work History | Cygnal Therapeutics, Roche Venture Fund, GSK, Merck & Co., DuPont, and Merck Research Ventures Fund | BioDuro, Galenea, Telephia, Genta, and McKinsey & Company | |||
Title | Founder | Founder, Chief Executive Officer | Senior Vice President | Senior Vice President | Managing General Partner |
Status | Current | Current | Current | Current | Current |
You May Also Like
Guangzhou Baiyunshan Pharmaceutical specializes in the development and production of Chinese patent medicines, biological products, health medicines, and health beverages, as well as the wholesale, retail, import, and export of Chinese medicine, western medicine, and medical equipment. It is based in Guangzhou, Guangdong.
Delova Biotech is a specialty branded pharmaceutical company, focusing on the development of proprietary formulations of injectable drug products to fulfill unmet medical needs in China and the US. The firm was founded in 2017 and is based in Nanjing, China.
Hua Medicine (华领医药) (HK: 02552) is a clinical-stage drug development company in China, focusing on therapies for the treatment of diabetes and CNS disorders.
China National Pharmaceutical Group is a Chinese medical and healthcare group directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC). Sinopharm's core businesses include distribution, retail, scientific research, and manufacture of healthcare-related products and owns wholly-owned or holding subsidiaries, and companies, including Sinopharm Group, China National Medicines, Sinopharm Accord Medicines, Tiantan Biological Products, Shanghai Shyndec Pharmaceutical, and China Traditional Chinese Medicine.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.